This article has been updated

A group of microbiome researchers discuss some of the challenges in developing a new generation of microbiome therapies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 19 November 2018

    In the HTML version of this article initially published online, Box 1 was missing. The error has been corrected online as of 19 November 2018.

References

  1. 1.

    , & Patents as early indicators of technology and investment trends: analyzing the microbiome space as a case study. Front. Bioeng. Biotechnol. 6, 84 (2018).

  2. 2.

    University of Chicago Technology Commercialization. Polsky Microbiome – Venture Funding Data. (2018).

Download references

Author information

Affiliations

  1. Gaspar Taroncher-Oldenburg is at Global Engage Ltd, Kidlington, Oxford, UK.

    • Gaspar Taroncher-Oldenburg
  2. Susan Jones is at Nature Biotechnology, London, UK.

    • Susan Jones
  3. Martin Blaser is at the New York University Langone Medical Center, New York, New York, USA.

    • Martin Blaser
  4. Richard Bonneau is at the Center for Genomics and Systems Biology, New York University, New York, New York, USA, and the Flatiron Institute, Center for Computational Biology, Simons Foundation, New York, New York, USA.

    • Richard Bonneau
  5. Peter Christey is at General Automation Lab Technologies, Inc (GALT), San Carlos, California, USA.

    • Peter Christey
  6. José C. Clemente is at the Icahn Institute for Genomics and Multiscale Biology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

    • José C Clemente
  7. Eran Elinav is in the Immunology Department, Weizmann Institute of Science, Rehovot, Israel.

    • Eran Elinav
  8. Elodie Ghedin is at the Center for Genomics & Systems Biology, New York University, New York, New York, USA.

    • Elodie Ghedin
  9. Curtis Huttenhower is at the Harvard T.H. Chan School of Public Health, Boston Massachusetts, USA.

    • Curtis Huttenhower
  10. Denise Kelly is at Seventure Partners, Paris, France.

    • Denise Kelly
  11. David Kyle is at Evolve BioSystems Inc, Davis, California, USA.

    • David Kyle
  12. Dan Littman is at the Kimmel Center for Biology and Medicine of the Skirball Institute and the Howard Hughes Medical Institute, New York University School of Medicine, New York, New York, USA.

    • Dan Littman
  13. Arpita Maiti is in Worldwide Research & Development, Pfizer, Inc, Cambridge, Massachusetts, USA.

    • Arpita Maiti
  14. Alexander Maue is at Taconic Biosciences, Renssaelaer, New York, USA.

    • Alexander Maue
  15. Bernat Olle is at Vedanta Biosciences, Inc., Cambridge, Massachusetts, USA.

    • Bernat Olle
  16. Leopoldo Segal is in the Division of Pulmonary and Critical Care Medicine, New York University School of Medicine, New York, New York, USA.

    • Leopoldo Segal
  17. Johan E. T. van Hylckama Vlieg is at Chr. Hansen, Hoersholm, Denmark.

    • Johan E T van Hylckama Vlieg
  18. Jun Wang is at iCarbonX, Zhonghang Shahe Industrial Zone, Shenzhen, China.

    • Jun Wang

Authors

  1. Search for Gaspar Taroncher-Oldenburg in:

  2. Search for Susan Jones in:

  3. Search for Martin Blaser in:

  4. Search for Richard Bonneau in:

  5. Search for Peter Christey in:

  6. Search for José C Clemente in:

  7. Search for Eran Elinav in:

  8. Search for Elodie Ghedin in:

  9. Search for Curtis Huttenhower in:

  10. Search for Denise Kelly in:

  11. Search for David Kyle in:

  12. Search for Dan Littman in:

  13. Search for Arpita Maiti in:

  14. Search for Alexander Maue in:

  15. Search for Bernat Olle in:

  16. Search for Leopoldo Segal in:

  17. Search for Johan E T van Hylckama Vlieg in:

  18. Search for Jun Wang in:

Competing interests

G.T.-O. is consultant-in-residence at Global Engage and became an advisor to the Janssen Human Microbiome Institute after completion of Microbiome Futures; M.B. serves on the scientific advisory boards of Elysium, Inc, Ubiome, Inc., Commense, Inc. and Seed, Inc.; R.B. has served as an expert witness for Kirkland and Ellis LLC, in advisory and consulting roles to the Simons Foundation, Novartis, Eli Lilly and Merus, and is currently collaborating with Novartis and Merus; P.C. is CEO and Co-Founder of General Automation Lab Technologies, Inc.; E.E. is a scientific consultant to DayTwo & BiomX; C.H. serves on the scientific advisory boards of Seres Therapeutics and Microbiome Insights; D. Kyle is an employee of, and owns shares in, Evolve BioSystems Inc.; D.L. is founder of and advisor to Vedanta, Director at Pfizer, Inc., and a recipient of research funding for microbiota projects from Boehringer Ingelheim; A. Maiti is an employee of Pfizer Inc.; A. Maue is an employee of Taconic Biosciences; B.O. is an employee of Vedanta Biosciences, a company developing drugs in the human microbiome field, and holds stock options in the company; J.E.T.v.H.V. is an employee of Chr. Hansen A/S; J.W. is founder & CEO of iCarbonX.

Corresponding author

Correspondence to Gaspar Taroncher-Oldenburg.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4287

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing